Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.1823
- Book/Share 15.7357
- PB 7.1485
- Debt/Equity 1.2679
- CurrentRatio 1.3154
- ROIC 0.149
- MktCap 140174305700.0
- FreeCF/Share 7.5253
- PFCF 14.9615
- PE 22.2861
- Debt/Assets 0.4477
- DivYield 0.0276
- ROE 0.3294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Upgrade | GILD | Daiwa Securities | Neutral | Outperform | -- | $128 | Aug. 19, 2025 |
Upgrade | GILD | Truist | Hold | Buy | -- | $127 | Aug. 8, 2025 |
Upgrade | GILD | Needham | Hold | Buy | -- | $133 | July 25, 2025 |
Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
Upgrade | GILD | Morgan Stanley | Equal Weight | Overweight | $87 | $113 | Jan. 10, 2025 |
Resumed | GILD | BofA Securities | -- | Buy | -- | $109 | Dec. 10, 2024 |
Upgrade | GILD | Leerink Partners | Market Perform | Outperform | $74 | $96 | Oct. 21, 2024 |
News
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.
Read More
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
Read More
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.
Read More
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
Read More
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Read More
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Final Trades: Gilead, Blackstone, Disney and Visa
Published: July 25, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Calls of the Day: Gilead, Chipotle and P&G
Published: July 25, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in the 7 major markets (US, France, Germany, Italy, Spain, UK, Japan). Optimize your strategic approach with pipeline insights and competitive assessment. Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in the 7 major markets (US, France, Germany, Italy, Spain, UK, Japan). Optimize your strategic approach with pipeline insights and competitive assessment.
Read More
Why Merck Is A Better Dividend Stock Than Gilead Sciences
Published: July 16, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate my Hold rating on Merck & Co., Inc. and downgrade Gilead Sciences, Inc. to Sell, as MRK outperforms on dividend growth and valuation metrics. Compared to GILD, MRK features a longer dividend growth streak, a higher recent dividend increase, and a superior PEGY ratio. Both companies have similar payout ratios and mixed buyback histories, but GILD's inventory management is notably better than MRK's.
Read More
WHO recommends Gilead's twice-yearly injection for HIV prevention
Published: July 14, 2025 by: Reuters
Sentiment: Positive
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.
Read More
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
Published: July 09, 2025 by: Benzinga
Sentiment: Negative
Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead's twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).
Read More
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Final Trades: Synovus, Nextera Energy, Gilead and the IYF
Published: July 08, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Gilead Sciences (GILD) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Read More
Gilead shares rise after US top court ruling on preventative coverage
Published: June 27, 2025 by: Reuters
Sentiment: Positive
Shares of Gilead rose nearly 3% after the U.S. Supreme Court on Friday preserved a key element of the Obamacare law that helps guarantee that health insurers cover preventive care at no cost to patients.
Read More
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Gilead partners with Kymera to develop novel cancer therapy
Published: June 25, 2025 by: Proactive Investors
Sentiment: Positive
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on developing a novel cancer treatment targeting cyclin-dependent kinase 2 (CDK2), a protein that plays a key role in tumor growth. This collaboration aims to accelerate the development and commercialization of a new class of drugs called molecular glue degraders (MDGs), which work by selectively removing the CDK2 protein from cancer cells rather than merely inhibiting its function.
Read More
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
Published: June 25, 2025 by: Reuters
Sentiment: Positive
Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel P. O'Day
- Employees 17600